B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines.

Ji, Sunhee; Lee, Jaeyeon; Lee, Eung Suk; Kim, Dae Hee; Sin, Jeong-Im

Ji, Sunhee; Lee, Jaeyeon; Lee, Eung Suk; Kim, Dae Hee; Sin, Jeong-Im.

Afiliação

Ji S; Department of Microbiology, School of Medicine, Kangwon National University, Chuncheon, Korea.
Lee J; Department of Microbiology, School of Medicine, Kangwon National University, Chuncheon, Korea.
Lee ES; Interdisciplinary Graduate Program in BIT Medical Convergence, Kangwon National University, Chuncheon, Korea.
Kim DH; Scripps Korea Antibody Institute, Chuncheon, Korea.
Sin JI; Scripps Korea Antibody Institute, Chuncheon, Korea.

Hum Vaccin Immunother ; 17(7): 1910-1922, 2021 07 03.

Article em En | MEDLINE | ID: mdl-33522416

Assuntos

Vacinas Anticâncer; Melanoma Experimental; Animais; Antígeno B7-H1; Linfócitos T CD8-Positivos; Linhagem Celular Tumoral; Humanos; Células Matadoras Naturais; Melanoma Experimental/terapia; Camundongos; Camundongos Endogâmicos C57BL; Peptídeos

Palavras-chave

Anti-PD-L1; cancer immunotherapy; melanoma; peptide vaccine

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Melanoma Experimental / Vacinas Anticâncer Limite: Animals / Humans Idioma: En Revista: Hum Vaccin Immunother Ano de publicação: 2021 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google